Patient’s Voice, sponsored by Merck, provides employers with insights into the needs and challenges of Canadian workers who are living with a chronic disease.
This latest installment to the Patient’s Voice series focuses on the unintended consequences that can arise from cost-containment strategies that focus primarily on short-term drug cost savings. Restricting access to medications may result in adverse health outcomes, treatment complications, poor productivity and increased use of healthcare services, thereby driving costs to employers rather than reducing them. Innovative plan designs, on the other hand, can improve adherence to treatment and employee health—and ultimately reduce costs.
The Patient’s Voice series began with a 2011 survey (conducted by Rogers Connect Market Research) of more than 200 plan members diagnosed with a chronic illness and more than 100 plan sponsors. The series, including three past installments below, discusses the research results, explores the impact of chronic illness on both employees and plan sponsors and recommends solutions.
Sponsored by:
